Completed PHASE3 INTERVENTIONAL 2-arm NCT00193908

Cavilon Breast Trial: Comparison of Cavilon Durable Barrier Cream to Glycerine (Sorbolene) Cream

A Paired Double Blind Randomised Comparison of Cavilon(TM) Durable Barrier Cream(TM)[CDBC] to 10% Glycerine (Sorbolene) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care

Sponsor: 3M

Conditions Breast Cancer

Interventions Cavilon (TM) Durable Barrier Cream Radiotherapy Sorbolene

Updated 5 times since 2017 Last updated: May 13, 2009 Started: Mar 31, 2004 Primary completion: Sep 30, 2007 Completion: Oct 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Breast Cancer and is currently completed. 3M leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

3M
Trans Tasman Radiation Oncology Group

Data source: Trans Tasman Radiation Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Geelong, Australia , Herston, Australia , Kogarah, Australia , Liverpool, Australia , Newcastle, Australia , Perth, Australia , Randwick, Australia , South Brisbane, Australia , Wentworthville, Australia and 2 more locations